Résumé
Human spleen, though being the largest component of reticuloendothelial system, is a very rare site of tumor metastases. Splenic metastases are usually seen as part of multi-organ involvement. Autopsy study conducted over a period of 10 years revealed that the incidence of neoplastic involvement of spleen was 1.45% (70/4812). Primary malignant involvement of spleen was also noted to be a rare entity in present study.
Sujets)
Adénocarcinome/anatomopathologie , Adolescent , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Autopsie , Enfant , Enfant d'âge préscolaire , Femelle , Humains , Incidence , Tumeurs du poumon/anatomopathologie , Lymphomes/anatomopathologie , Mâle , Adulte d'âge moyen , Rate/anatomopathologie , Tumeurs spléniques/épidémiologieRésumé
This is a case report of a mesenchymal tumor of uterus in a 60 year female initially interpreted as myxoid leiomyosarcoma. Immunohistochemical studies were negative for smooth muscle actin, desmin and p53 but positive for S-100 protein. The tumor was therefore reclassified as a low grade malignant mesenchymal tumor of neural origin.
Sujets)
Diagnostic différentiel , Femelle , Humains , Immunohistochimie , Léiomyosarcome/diagnostic , Adulte d'âge moyen , Protéines S100/métabolisme , Sarcomes/diagnostic , Tumeurs de l'utérus/diagnosticRésumé
Human peripheral blood lymphocytes stimulated in vitro for 6 hr were exposed to a low (conditioning) dose of ethyl methanesulfonate (EMS; 1.5 x 10(-4) M) or methyl methanesulfonate (MMS; 1.5 x 10(-5) M). After 6 hr, the cells were treated with a high (challenging) concentration of the same agent (1.5 x 10(-3) M EMS or 1.5 x 10(-4) M MMS). The cells that received both conditioning and challenging doses became less sensitive to the induction of sister chromatid exchanges (SCEs) than those which did not receive the pretreatment with EMS or MMS. They responded with lower frequencies of SCEs. This suggests that conditioning dose of EMS or MMS has offered the lymphocytes to have decreased SCEs. This led to the realization that pre-exposure of lymphocytes to low dose can cause the induction of repair activity. This is a clear indication of the existence of adaptive response induced by alkylating agents whether it is ethylating or methylating in human lymphocytes in vitro.
Sujets)
Adaptation physiologique , Adulte , Agents alcoylants/administration et posologie , Méthanesulfonate d'éthyle/administration et posologie , Humains , Lymphocytes/effets des médicaments et des substances chimiques , Mâle , Méthanesulfonate de méthyle/administration et posologie , Échange de chromatides soeurs/effets des médicaments et des substances chimiquesRésumé
To investigate the induction of adaptive response (inducible protective processes) in mitotic cells of Swiss albino mouse, a monofunctional alkylating agent methyl methanesulfonate (MMS) was employed. When the animals treated with a low dose of 50 mg/kg body weight were challenged with a subsequent high (challenging) dose of 150 mg/kg body weight, after different time lags (2,5,8 or 10 hr), the yield of chromosomal aberrations in bone marrow cells was found to be significantly reduced compared to the additive effects of both conditioning and challenging doses. It seems, therefore, that the low dose of MMS employed has made the cells less sensitive against further clastogenic effect of challenge dose of MMS. The data clearly suggest that the phenomenon of adaptive response to methylating agents can be encountered in in vivo mammalian cells. Furthermore, it is also observed that ethylating agent EMS is a poor inducer of adaptive response than its corresponding methylating agent MMS in the bone marrow cells of mouse.